MARKET

FENC

FENC

Fennec Pharmaceuticals Inc
NASDAQ
7.55
-0.23
-2.96%
After Hours: 7.55 0 0.00% 17:01 12/05 EST
OPEN
7.75
PREV CLOSE
7.78
HIGH
7.88
LOW
7.43
VOLUME
71.14K
TURNOVER
--
52 WEEK HIGH
9.92
52 WEEK LOW
4.680
MARKET CAP
212.28M
P/E (TTM)
-29.9247
1D
5D
1M
3M
1Y
5Y
1D
Director Rosty Raykov Reports Sale of Fennec Pharmaceuticals Inc. Common Shares
Reuters · 1d ago
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
Benzinga · 4d ago
Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan
TipRanks · 5d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 5d ago
Fennec announces Phase 2/3 STS-J01 trial met primary endpoint
TipRanks · 5d ago
Fennec Pharmaceuticals Released Topline Results From Phase 2/3 STS-J01 Trial Of Pedmark (Sodium Thiosulfate Injection) For The Reduction Of Cisplatin-induced Ototoxicity In Pediatric And Adolescent And Young Adult Patients With Non-metastatic Solid Tumors In Japan
Benzinga · 5d ago
Fennec Pharmaceuticals Reports Positive Results for PEDMARK in Japanese Pediatric Cancer Study
Reuters · 5d ago
FENNEC PHARMACEUTICALS INC - PLANS TO PURSUE REGISTRATION FOR PEDMARK IN JAPAN
Reuters · 5d ago
More
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Webull offers Fennec Pharmaceuticals Inc stock information, including NASDAQ: FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.